Europe Western Blotting Market

Europe Western blotting market Size (2023 to 2028)

The size of the European Western blotting market is valued at USD 126.71 million in 2023. It is expected to reach USD 164.05 million by 2028, at a 5.3% CAGR during the forecast period.

Factors such as Y-O-Y growth in the incidence of HIV, growing expenditure by the companies on the R&D, the existence of favorable reimbursement policies, and government amendments are majorly boosting the growth of the western blotting market in the European region. Growth strategies adopted by key companies such as mergers, acquisitions, the launch of new product developments, partnerships, and distribution agreements are further expected to fuel market growth. Growing awareness regarding western blotting is another significant contributor to market growth in the European region.

The availability of alternative technological methods is expected to hamper the market growth to a small extent. Skilled and expert lab technicians are needed to execute the technique is to impede the market.

This research report on the Europe Western Blotting Market has been segmented and sub-segmented into the following categories:

• By Product: Instruments and Consumables
• By Application: Biomedical & Biochemical Research and Disease Diagnostics
• By End User: Academic & Research Institutes, Pharmaceutical, and Biotechnology Companies
• By Country: UK, France, Spain, Germany, Italy, Russia, Sweden, Denmark, Switzerland, Netherlands, Turkey, Czech Republic, and Rest of Europe

Regional Analysis:

Europe had the second-largest share in the global market in 2019. It can be attributed to factors such as growth in the proteomics market, the increasing number of industry-academic research collaborations, and the increase in personalized medicine requirements.

In this region, Germany is expected to lead the European Western Blotting Market during the forecast period due to the appearance of well-developed and mature organizations in the country and also rising innovative technologies that drive to the growth of the market.

The UK is next in line with accounting majority market share in the market during the forecast period. The growing prevalence of Lyme and HIV diseases and increasing demand for proteomics and growing investments in the proteomics segment favor the UK market.

Key players operating in the Europe Western blotting market profiled in this report are Bio-Rad Laboratories, Inc., Thermo Fisher Scientific, Inc., GE Healthcare, Advansta, Inc., LI-COR Biosciences, PerkinElmer Inc., Bio-Techne Corporation, Merck KGaA, F. Hoffmann-La Roche Ltd., and Cell Signaling Technology.